NEWS

While some in Washington are proposing damaging drug pricing policies, including “Most Favored Nation,” China is gaining ground in...

A common depiction of a U.S. biopharmaceutical industry worker shows someone working alone in a sterile lab environment. They wear a...

American innovation has long been the envy of the world, built on a foundation of strong intellectual property protections,...

By Dan Leonard, Executive Director, We Work For Health Global innovation is a long-distance race. For decades, the United States has led...

By: Dan Leonard, Executive Director, We Work For Health The Administration’s latest proposal to revive the Most Favored Nation (MFN) drug...

By Dan Leonard, Executive Director, WWFH The Inflation Reduction Act (IRA), signed into law in August 2022, contains a healthcare...

This Saturday, we observe World Intellectual Property Day , a moment to reflect on how intellectual property (IP) rights enable...

By Tom Kowalski, WWFH Co-Chair Chronic disease has contributed to declining life expectancy in the United States , a disturbing pattern...

The lead sponsors of the Ensuring Pathways to Innovative Cures (EPIC) Act addressed a room full of Congressional office employees and...

Learn about the Inflation Reduction Act—and how it’s threatening America’s biopharmaceutical ecosystem and our nation’s Medicare-aged...

Innovation often comes in increments. The first smartphones could not record video or take front-facing photos, and there certainly was...

A new report highlights the significant investments and economic impact generated by clinical trials funded by the biopharmaceutical...

Healthcare costs continue to be a significant concern for Americans. While policies like government price controls under the Inflation...

Small-molecule drugs, which typically come in pill or tablet form, have long been the backbone of modern medicine, treating everything...

Throughout 2024, the pharmaceutical industry announced $31 billion  in confirmed investment commitments across the United States,...

Research firm Vital Transformation is preparing a new analysis about the impacts of the Inflation Reduction Act on biopharma investment,...

At We Work For Health (WWFH), our commitment to fostering health equity across the nation goes beyond advocacy—it extends to tangible,...

The biopharmaceutical industry is the backbone of America's innovative economy, supporting more than 4.9 million jobs across the United...

As Congress returned to Washington, the Senate Judiciary Committee held a full committee hearing  to consider a number of critical bills...

New research from the IQVIA Institute for Human Data Science further confirms what We Work For Health (WWFH) and others have warned...